Balloon Dilation in Sporadic Inclusion Body Myositis Patients with Dysphagia

Murata, Kenya; Kouda, Ken; Tajima, Fumihiro; Kondo, Tomoyoshi

doi:10.4137/ccrep.s10200

Cited by 37 publications

(36 citation statements)

References 15 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[65] Caution is suggested in recommending cricopharyngeal myotomy as there is a report of worsening after that procedure in a patient who also had a hiatal hernia. [66]…”

Section: Therapymentioning

confidence: 99%

Inclusion Body Myositis

Dimachkie

Barohn

2014

Neurologic Clinics

View full text Add to dashboard Cite

The idiopathic inflammatory myopathies (IIM) are a heterogenous group of rare disorders that share many similarities. In addition to sporadic inclusion body myositis (IBM), these include dematomyositis (DM), polymyositis (PM), and autoimmune necrotizing myopathy (NM). For discussion of later three disorders, the reader is referred to the IIM review in this issue. IBM is the most common IIM after age 50. It typically presents with chronic insidious proximal leg and/or distal arm asymmetric muscle weakness leading to recurrent falls and loss of dexterity. Creatine kinase (CK) is up to 15 times elevated in IBM and needle electromyograhy (EMG) mostly shows a chronic irritative myopathy. Muscle histopathology demonstrates endomysial inflammatory exudates surrounding and invading non-necrotic muscle fibers often times accompanied by rimmed vacuoles and protein deposits. Despite inflammatory muscle pathology suggesting similarity with PM, it likely that IBM is has a prominent degenerative component as supported by refractoriness to immunosuppressive therapy. We review the evolution of our knowledge in IBM with emphasis on recent developments in the field and discuss ongoing clinical trials.

show abstract

“…[65] Caution is suggested in recommending cricopharyngeal myotomy as there is a report of worsening after that procedure in a patient who also had a hiatal hernia. [66]…”

Section: Therapymentioning

confidence: 99%

Inclusion Body Myositis

Dimachkie

Barohn

2014

Neurologic Clinics

View full text Add to dashboard Cite

show abstract

“…Major side effects of alemtuzumab are the development of an autoimmune thyroiditis or idiopathic thrombocytopenic purpura . In three controlled prospective studies with IVIG, no increase of the limb strength could be observed , whereas the dysphagia was improved significantly .…”

Section: Introductionmentioning

confidence: 99%

“…Other uncontrolled studies, each with a small number of patients, addressed the effect of the following interventions in IBM: cricopharyngeal myotomy, pharyngoesophageal dilatation, percutaneous endoscopic gastrostomy (PEG) and injection of botulinum toxin. A benefit was shown for both myotomy and dilatation, but the results were limited by the number of only 10 patients . So far, treatment with botulinum toxin has shown different results, ranging between no effect and improvement in swallowing for several months .…”

Section: Introductionmentioning

confidence: 99%

Diagnosis, pathogenesis and treatment of myositis: recent advances

Carstens

Schmidt

2014

Clinical and Experimental Immunology

108

View full text Add to dashboard Cite

Diagnosis, pathogenesis and treatment of myositis: recent advances OTHER ARTICLES PUBLISHED IN THIS SERIESParaneoplastic neurological syndromes. Clinical and Experimental Immunology 2014, 175: 336-48. Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies. Clinical and Experimental Immunology 2014, 175: 359-72

show abstract

“…In controlled prospective studies, IVIG had improved dysphagia [ 45,46,47] , but had no impact in increasing of the limb strength [47][48][49][50].…”

Section: Intravenous Immunoglobulin (Ivig)mentioning

confidence: 99%

Current pharmacological treatment of idiopathic inflammatory myopathies

Fasano

Alves²,

Isenberg

2016

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

The idiopathic inflammatory myopathies are uncommon and heterogeneous disorders. Their classification is based on distinct clinicopathologic features. Although idiopathic inflammatory myopathies share some similarities, different subtypes may have variable responses to therapy, so it is very important to distinguish the correct subtype.There are few randomised, double blind placebo controlled studies to support the current treatment.High dose corticosteroids continue to be the first line therapy and other immunosupressive drugs are used in refractory cases, as well as steroid-sparing agents.Some novel therapeutic approaches have emerged as potential treatment including tacrolimus, intravenous immunoglobulin and rituximab, following good outcomes reported in case studies.However, more randomised controlled trials are needed.This review considers the current and the potential future therapies for inflammatory myopathies.

show abstract

Balloon Dilation in Sporadic Inclusion Body Myositis Patients with Dysphagia

Cited by 37 publications

References 15 publications

Inclusion Body Myositis

Inclusion Body Myositis

Diagnosis, pathogenesis and treatment of myositis: recent advances

Current pharmacological treatment of idiopathic inflammatory myopathies

Contact Info

Product

Resources

About